Spica Therapeutics
Spica Therapeutics is a biotechnology company dedicated to transforming the treatment of cancer, fibrosis and inflammatory diseases through precision targeting macrophage biology. Founded on pioneering research from Aarhus University, the company utilizes a proprietary functional fingerprinting platform to identify and deplete specific pathogenic macrophage subsets while preserving beneficial immune cells. Headquartered in Antwerp, Belgium, Spica is backed by a syndicate of leading life science investors.Content by Spica Therapeutics
| 2 min read
ProBioGen will apply its CHO.RiGHT platform and GlymaxX technology to support Spica’s first clinical candidate, the anti-CD163 antibody ST101.
Page 1 of 1 - 1 Total Items
